Thompson Investment Management Inc. Cuts Stock Holdings in GSK plc (NYSE:GSK)

Thompson Investment Management Inc. trimmed its stake in GSK plc (NYSE:GSK) by 19.4% during the 4th quarter, Holdings Channel reports. The firm owned 2,293 shares of the pharmaceutical company’s stock after selling 553 shares during the quarter. Thompson Investment Management Inc.’s holdings in GSK were worth $78,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. SG Americas Securities LLC raised its position in shares of GSK by 167.3% during the 3rd quarter. SG Americas Securities LLC now owns 18,773 shares of the pharmaceutical company’s stock valued at $767,000 after buying an additional 11,749 shares in the last quarter. Brookstone Capital Management increased its stake in GSK by 2.8% in the third quarter. Brookstone Capital Management now owns 26,457 shares of the pharmaceutical company’s stock valued at $1,082,000 after acquiring an additional 718 shares during the last quarter. Ritholtz Wealth Management raised its position in GSK by 2.8% during the third quarter. Ritholtz Wealth Management now owns 78,540 shares of the pharmaceutical company’s stock valued at $3,211,000 after purchasing an additional 2,143 shares in the last quarter. Gilman Hill Asset Management LLC raised its position in GSK by 9.7% during the third quarter. Gilman Hill Asset Management LLC now owns 67,422 shares of the pharmaceutical company’s stock valued at $2,756,000 after purchasing an additional 5,965 shares in the last quarter. Finally, Thomasville National Bank lifted its stake in GSK by 2.5% during the third quarter. Thomasville National Bank now owns 475,384 shares of the pharmaceutical company’s stock worth $19,434,000 after purchasing an additional 11,771 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently weighed in on GSK. Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and decreased their price objective for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research report on Thursday, October 31st. StockNews.com upgraded shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday. Finally, Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Six equities research analysts have rated the stock with a hold rating and four have assigned a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Stock Performance

Shares of GSK stock opened at $36.03 on Monday. The company has a market capitalization of $74.68 billion, a P/E ratio of 22.66, a PEG ratio of 1.42 and a beta of 0.64. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.53 and a current ratio of 0.78. The stock has a 50 day moving average price of $34.25 and a two-hundred day moving average price of $37.56.

GSK (NYSE:GSK) last posted its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 EPS for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a net margin of 8.13% and a return on equity of 48.59%. Analysts expect that GSK plc will post 4.07 earnings per share for the current year.

GSK Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 10th. Investors of record on Friday, February 21st will be paid a $0.3932 dividend. The ex-dividend date is Friday, February 21st. This is a boost from GSK’s previous quarterly dividend of $0.39. This represents a $1.57 annualized dividend and a dividend yield of 4.36%. GSK’s dividend payout ratio (DPR) is presently 93.08%.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.